[ad_1]
Sputnik V, the first registered Russian vaccine against covid-19, has proven to be effective in 92% of cases, according to the first results of the tests published this Wednesday by the Gamaleya Center and the Fund for Direct Investments of Russia (FIDR).
“The first interim data analyzes of the Sputnik V vaccine against covid-19 during the third phase of the trials showed an efficacy of 92%,” indicated the developer of the preparation and the Russian sovereign wealth fund.
(Don’t stop reading: Pfizer says its coronavirus vaccine gives 90% protection)
According to the joint statement, this result was obtained in an investigation with more than 16,000 volunteers 21 days after receiving the first dose of the vaccine, which is inoculated in two doses, or a placebo.
(You may be interested in: Colombia prepares plan for a potential coronavirus vaccine)
“In the statistical analysis, 20 confirmed cases of the disease (covid-19) were included, by whose distribution (in the group that was vaccinated and in the one that received the placebo) it was established that the efficacy of the Sputnik V vaccine was 92 % “, adds the note.
To date, according to the developers of the preparation, in 29 medical centers in the country 20,000 volunteers have received the first dose of the vaccine and more than 16,000 the two doses of the preparation.
In the statistical analysis, 20 confirmed cases of the disease (covid-19) were included, by whose distribution it was established that the efficacy of the Sputnik V vaccine was 92%
“In the course of the investigation, no unexpected side effects have been detected. In part of the vaccinated, temporary effects were observed such as pain at the site of inoculation of the vaccine, flu symptoms with increased body temperature, weakness, fatigue and headache, “the statement added.
The observation of the study participants will continue for another six months, after which the final results will be published, stressed the Gamaleya Center and the FIDR.
(Also watch this video: ‘The vaccine will be free for the whole country’, Ministry of Health)
A “detailed” study is also being carried out on the safety of the vaccine and immunogenesis in older people. Russia assures that the data will be published by researchers from the Gamaleya Center in one of the main medical journals after an independent evaluation by expert epidemiologists.
The Russian Minister of Health, Mikhail Murashkin, stressed that the results of the Sputnik V clinical tests “show that it is an effective means to stop the spread of the coronarvirus, prevent the disease, which is the best way to defeat the pandemic. “
The director of the Gamaleya Center, Alexandr Gintsburg, pointed out that the publication of the preliminary results “opens the way to mass vaccination in Russia against covid-19 in the coming weeks.”
The director of the FIDR, Kirill Dimítriev, recalled that the Russian vaccine uses human adenovirus as a vector and not mono or mRNA adenovirus vectors, as Russia often highlights.
The US pharmaceutical Pfizer announced this week that its vaccine against covid-19 is 90% effective, above what is required by US regulators, which allows to predict a quick emergency authorization for its making available to the public.
EFE
